Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Tonix Pharmaceuticals Holding's highest Cyclically Adjusted PB Ratio was 0.01. The lowest was 0.01. And the median was 0.01.
FRA:TPM0's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Tonix Pharmaceuticals Holding's adjusted book value per share data for the three months ended in Jun. 2026 was €10.678. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €84,072,829.18 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Tonix Pharmaceuticals Holding (FRA:TPM0) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Tonix Pharmaceuticals Holding Cyclically Adjusted PB Ratio Related Terms
Tonix Pharmaceuticals Holding Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding Cyclically Adjusted PB Ratio Chart
FRA:TPM0 vs RNA, NERV, GLSI: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio falls into.
Tonix Pharmaceuticals Holding Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.00 mean?
Tonix Pharmaceuticals Holding (FRA:TPM0) has a Cyclically Adjusted PB Ratio of 0.00 as of Sep. 22, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Tonix Pharmaceuticals Holding and its competitors. Over the past decade, Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio has ranged from 0.01 to 0.01. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #999999 out of 679 companies in the Biotechnology industry.
Is Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio too high?
Tonix Pharmaceuticals Holding's current Cyclically Adjusted PB Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.01. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #999999 out of 679 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Cyclically Adjusted PB Ratio compare to RNA and NERV?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #999999 out of 679 companies for Cyclically Adjusted PB Ratio. This places Tonix Pharmaceuticals Holding in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.57. Historically, Tonix Pharmaceuticals Holding's own Cyclically Adjusted PB Ratio has ranged from 0.01 to 0.01 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.57, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Tonix Pharmaceuticals Holding and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current Cyclically Adjusted PB Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (FRA:TPM0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.37, compared to a current price of €8.96 — trading 2320.5% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.00. Tonix Pharmaceuticals Holding's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (FRA:TPM0), the current Cyclically Adjusted PB Ratio is 0.00 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (FRA:TPM0) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of €8.96 is trading 2320.5% above its estimated GF Value™ of €0.37.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for FRA:TPM0:
Cyclically Adjusted PB Ratio: 0.00
GF Value™: €0.37 vs. price of €8.96 (2320.5% above fair value)
No single metric tells the full story. See the FRA:TPM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company based in the United States that develops and commercializes therapeutics for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its lead program, TNX-102 SL (tonmya), is a sublingual cyclobenzaprine formulation under development for fibromyalgia and other conditions such as post-traumatic stress disorder. The company also markets acute migraine products, including Zembrace SymTouch and Tosymra, through its commercial operations. Its pipeline includes immunology candidates such as TNX-1500, a CD40 ligand inhibitor being developed to prevent organ transplant rejection, and TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, along with vaccine and antiviral programs. Revenue comes from sales of its marketed migraine products and, historically, from government research contracts. The company operates primarily in the United States.
26GF Score
Get the complete analysis for FRA:TPM0
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TPM0 has been successfully added to your 
